Table 4 Correlation of ZEB1-AS1(T1-4) and ZEB1-AS1(T5,6) expression with clinicopathological features in luminal BC patients
Characteristics | No. of cases (total: 79) | ZEB1-AS1(T1-4) expression level | ZEB1-AS1(T5,6) expression level | ||||
|---|---|---|---|---|---|---|---|
Low N (%) | High N (%) | P-value | Low N (%) | High N (%) | P-value | ||
Age at diagnosis (2 missing, n = 77) | |||||||
≤ 40 | 20 | 12 (30.8%) | 8 (21.1%) | 0.33 | 12 (31.6%) | 8 (20.5%) | 0.26 |
> 40 | 57 | 27 (69.2%) | 30 (78.9%) | 26 (68.4%) | 31 (79.5%) | ||
Tumor size (1 missing, n = 78) | |||||||
< 2 cm | 23 | 11 (28.9%) | 12 (30.0%) | 0.15 | 10 (25.7%) | 13 (33.3%) | 0.25 |
2–5 cm | 41 | 17 (44.8%) | 24 (60.0%) | 24 (61.5%) | 17 (43.6%) | ||
> 5 cm | 14 | 10 (26.3%) | 4 (10.0%) | 5 (12.8%) | 9 (23.1%) | ||
Tumor subtype (n = 79) | |||||||
Luminal A | 65 | 36 (90.0%) | 29 (74.4%) | 0.07 | 32 (80.0%) | 33 (84.6%) | 0.59 |
Luminal B | 14 | 4 (10.0%) | 10 (25.6%) | 8 (20.0%) | 6 (15.4%) | ||
Grade (n = 79) | |||||||
1 | 11 | 6 (15.0%) | 5 (12.8%) | 0.80 | 6 (15.0%) | 5 (12.8%) | 0.80 |
2 | 54 | 28 (70.0%) | 26 (66.7%) | 26 (65%) | 28 (71.8%) | ||
3 | 14 | 6 (15.0%) | 8 (20.5%) | 8 (20.0%) | 6 (15.4%) | ||
Stage (2 missing, n = 77) | |||||||
I | 6 | 3 (7.9%) | 3 (7.7%) | 0.94 | 3 (7.7%) | 3 (7.9%) | 0.82 |
II | 42 | 20 (52.6%) | 22 (56.4%) | 20 (51.3%) | 22 (57.9%) | ||
III | 29 | 15 (39.5%) | 14 (35.9%) | 16 (41.0%) | 13 (34.2%) | ||
Pathology of tumors (7 missing, n = 72) | |||||||
DCIS | 3 | 1 (2.6%) | 2 (5.9%) | 0.20 | 1 (2.8%) | 2 (5.6%) | 0.32 |
LCIS | 3 | 3 (7.9%) | 0 (0.0%) | 0 (0.0%) | 3 (8.3%) | ||
IDC | 57 | 29 (76.3%) | 28 (82.4%) | 30 (83.3%) | 27 (75.0%) | ||
ILC | 4 | 1 (2.6%) | 3 (8.8%) | 3 (8.3%) | 1 (2.8%) | ||
Others | 5 | 4 (10.6%) | 1 (2.9%) | 2 (5.6%) | 3 (8.3%) | ||
Progesterone receptor (n = 79) | |||||||
Negative | 10 | 4 (10.0%) | 6 (15.4%) | 0.47 | 4 (10.0%) | 6 (15.4%) | 0.47 |
Positive | 69 | 36 (90.0%) | 33 (84.6%) | 36 (90.0%) | 33 (84.6%) | ||
Estrogen receptor (n = 79) | |||||||
Negative | 0 | 0 (0.0%) | 0 (0.0%) | – | 0 (0.0%) | 0 (0.0%) | – |
Positive | 79 | 40 (100.0%) | 39 (100.0%) | 40 (100.0%) | 39 (100.0%) | ||
HER2 (n = 79) | |||||||
Negative | 70 | 37 (92.5%) | 33 (84.6%) | 0.69 | 36 (90.0%) | 34 (87.2%) | 0.69 |
Positive | 9 | 3 (7.5%) | 6 (15.4%) | 4 (10.0%) | 5 (12.8%) | ||